HOAP-Bleo As Salvage Therapy for Diffuse Aggressive Non-Hodgkin's Lymphoma
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A total of 30 patients with recurrent or unresponsive diffuse, aggressive non-Hodgkin's lymphoma, who had previously received doxorubicin, cyclophosphamide, vincristine, and prednisone with or without bleomycin were treated with a combination of doxorubicin, vincristine, ara C, prednisone, and bleomycin (HOAP-Bleo). Complete remissions were achieved in 33.3% of the patients and partial remissions in 13.3%. Four of the ten complete responders relapsed at 4, 10, 11, and 18 months. Myelosuppression was the major toxicity and nonhematological toxicities were acceptable. Their median survival from the date of first relapse was only 4-5 months.
References
1.
Cabanillas F, Burgess M, Bodey G, Freireich E
. Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. Am J Med. 1983; 74(3):382-8.
DOI: 10.1016/0002-9343(83)90955-5.
View
2.
Klimo P, Connors J
. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985; 102(5):596-602.
DOI: 10.7326/0003-4819-102-5-596.
View
3.
Schein P, Devita Jr V, Hubbard S, Chabner B, Canellos G, Berard C
. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med. 1976; 85(4):417-22.
DOI: 10.7326/0003-4819-85-4-417.
View
4.
SKARIN A, Canellos G, Rosenthal D, Case Jr D, MacIntyre J, Pinkus G
. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983; 1(2):91-8.
DOI: 10.1200/JCO.1983.1.2.91.
View
5.
Simon R
. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986; 105(3):429-35.
DOI: 10.7326/0003-4819-105-3-429.
View